Registration problems for antiretrovirals in Africa

Lancet

Volumn 367, Issue 9513, 2006, Pages 794-795

  Ford, Nathan ^a   Darder, Marta ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL;

AFRICA; DEVELOPED COUNTRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MARKETING; DRUG SUBSTITUTION; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; NOTE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 33644847772     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68313-X     Document Type: Note

References (4)

1. Guidelines development Group Antiretroviral drugs for the treatment of HIV infection in resource-limited settings: recommendations for a public health approach http://www.who.int/3by5/mediacentre/news51/en June 22-23, 2005 (accessed on March 2, 2006)
2. A Boulle, G Van Custem, D Goetzec Antiretroviral drugs for the treatment of HIV infection in resource-limited settings: recommendations for a public health approach http://who.int/3by5/mediacentre/news51/en June 22-23, 2005 (accessed March 2, 2006)
3. Gilead Gilead Sciences to provide access to anti-HIV therapy Viread® in 68 developing world countries at no profit http://www.gilead.com/wt/sec/ pr_1040081128 Dec 17, 2002 (accessed on March 2, 2006)
4. Gilead Gilead expands global access program for HIV therapies to include additional countries in the Caribbean and Latin America; Bahamas manufacturing plant established http://www.gilead.com/wt/sec/pr_686106 March 16, 2005 (accessed on March 2, 2006)